Basic Information
| LncRNA/CircRNA Name | LINC00162 |
| Synonyms | PICSAR, C21orf113, LINC00162, NCRNA00162, NLC1-C, NLC1C, PRED74 |
| Region | GRCh38_21:44999208-45004727 |
| Ensemble | ENSG00000275874 |
| Refseq | NR_024089 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | pancreatic ductal adenocarcinoma |
| ICD-0-3 | C25.3 |
| Methods | RNA-seq, in vitro knockdown etc |
| Sample | cancer cell lines (AsPc-1, BxPc-3, Panc-1, Pan28, Miapaca 2) |
| Expression Pattern | up-regulated |
| Function Description | Expression of LINC00162 is dramatically upregulated in PATC and PDAC cells.??INC00162 affects proliferation, colony formation and migration of PATC cells |
| Pubmed ID | 32364285 |
| Year | 2020 |
| Title | The overexpression of long intergenic ncRNA00162 induced by RelA/p65 promotes growth of pancreatic ductal adenocarcinoma. |
External Links
| Links for LINC00162 | GenBank HGNC NONCODE |
| Links for pancreatic ductal adenocarcinoma | OMIM COSMIC |